Weight Loss & Metabolic Peptides

10mg · Lyophilized powder

Semaglutide is a 31-amino acid GLP-1 receptor agonist based on the GLP-1(7-37) sequence with two key modifications: an Aib substitution at position 8 (protects against DPP-4 degradation) and a C-18 fatty diacid linker at position 26 (albumin binding for half-life extension). It has been studied in multiple large-scale clinical trial programs including SUSTAIN, PIONEER, and STEP, with over 20,000 total trial participants.

10mg · Lyophilized powder

Tirzepatide is a 39-amino acid dual GIP/GLP-1 receptor agonist based on the native GIP sequence. It incorporates a C-20 fatty diacid moiety for albumin binding and includes amino acid substitutions enabling GLP-1R cross-reactivity while maintaining GIPR activity. Studied in the SURPASS and SURMOUNT clinical trial programs with over 15,000 participants. The SURPASS-2 trial is the only published head-to-head comparison with semaglutide.

10mg · Lyophilized powder

Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously — the first peptide to engage all three pathways. Early phase clinical trial results published in the New England Journal of Medicine showed dose-dependent responses across metabolic parameters. The triple-agonist mechanism is a novel approach that goes beyond existing dual-agonist compounds.